XML 131 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:        
Research and development $ 28,834 $ 19,902 $ 58,312 $ 38,456
Selling, general and administrative 12,745 9,345 24,143 18,172
Total operating expenses 41,579 29,247 82,455 56,628
Loss from operations (41,579) (29,247) (82,455) (56,628)
Other income (expense):        
Research and development incentives 574 725 1,425 1,513
Investment income 1,112 80 1,455 172
Interest expense on finance lease liability (550) (557) (1,102) (1,115)
Other (expense) income (2,659) (356) (4,678) (608)
Total other (expense) income, net (1,523) (108) (2,900) (38)
Net loss $ (43,102) $ (29,355) $ (85,355) $ (56,666)
Net loss per share attributable to common stockholders, basic (in dollars per share) $ (0.79) $ (0.56) $ (1.57) $ (1.09)
Net loss per share attributable to common stockholders, diluted (in dollars per share) $ (0.79) $ (0.56) $ (1.57) $ (1.09)
Weighted average common shares outstanding, basic (in shares) 54,770,291 52,081,325 54,492,395 51,962,795
Weighted average common shares outstanding, diluted (in shares) 54,770,291 52,081,325 54,492,395 51,962,795